Ricevi le ultime notizie sulle azioni Mineralys Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di MLYS

Ultime notizie per

Mineralys Therapeutics

Mineralys Therapeutics, Inc. - Common Stock

Panoramica

Notizie

Utili

Opzioni

Insider trading

Vendite allo scoperto

Rapporto azionario

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Comments

Mineralys Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO